Latest Innovation News

NOVONIX has delivered its first commercial-grade synthetic graphite sample at mass production scale, marking a key step toward expanding its battery and industrial materials footprint.

ReNerve Ltd is rapidly advancing its nerve repair product portfolio, with four ranges expected on the market by the end of 2025 and expanding global distribution. Clinical studies highlight significant patient benefits, supporting the company’s growth in a booming biomaterials market.

Zeotech Limited has successfully raised $13 million through a strongly supported placement, positioning the company to advance mining operations at its Toondoon Kaolin Project and progress its AusPozz™ feasibility study.

Vection Technologies has agreed to acquire Australian digital transformation firm DXLabs, adding immediate revenue and expanding its footprint across APAC with promising cross-sell opportunities.

Bellavista Resources reports promising initial bioleaching results from its Brumby Project, confirming recovery of key critical minerals and advancing plans for bulk sample testing.

Metal Powder Works Limited reports its FY25 annual results, highlighting the accounting treatment of its reverse acquisition and a significant goodwill write-off tied to legacy operations.

Janus Electric has inked a $5 million share placement and exclusive distribution deal with EVUNI, setting the stage for its heavy transport electrification technology to enter the sub-Saharan region.

Chimeric Therapeutics reports encouraging early clinical trial outcomes for its CHM CDH17 CAR-T therapy, showing disease control and tumour shrinkage at higher dose levels with a strong safety profile.

Bravura Solutions has appointed Colin Greenhill as its new Group CEO, effective 1 January 2026, following a comprehensive global search. Greenhill brings over 15 years of leadership experience in financial services software, signaling a strategic step forward for the company.

EMVision Medical Devices launches a $2 million Share Purchase Plan offering shares at a 16.4% discount, bundled with free options exercisable at $3.40, aiming to bolster clinical and commercial milestones.

Synlait has agreed to sell its North Island assets to global healthcare giant Abbott for approximately US$178 million, marking a strategic reset focused on debt reduction and operational simplification. The deal, expected to close by April 2026, positions Synlait to concentrate on its South Island operations and explore new growth avenues.

FBR Limited has successfully placed the shortfall from its recent Share Purchase Plan, raising an additional $288,910 through issuing over 64 million shares. This capital injection supports the company’s ongoing development of its innovative robotic technologies.